Metformin and aging: a review of molecular effects and the proposed TAME trial
This abstract reviews how metformin, a first-line type 2 diabetes drug, may influence hallmarks of aging at molecular and organismal levels, and describes the planned TAME trial on age-associated diseases. It calls for more studies. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract says metformin acts by activating AMPK, leading to downstream events such as mTOR inhibition, increased mitochondrial biogenesis, autophagy and epigenetic modifications. [1]
Current findings reportedly show metformin can alter gut microbiota by increasing short-chain fatty acid producing bacteria. [1]
The TAME trial is described as seeking to evaluate whether metformin can slow several age-associated diseases. [1]
The source at a glance
- Study type / format
- Review article abstract
- Population / context
- Not specified in the abstract; described in general terms of cellular, molecular and organismal research on metformin and aging.
- Summary based on
- Study abstract
- Original publication
- August 10, 2026
Metformin's molecular actions beyond glucose lowering
The abstract describes metformin as a biguanide and first-line drug for type 2 diabetes. Besides lowering blood glucose, it says metformin acts by activating AMPK, which leads to downstream events such as inhibition of mTOR, increased mitochondrial biogenesis, autophagy and epigenetic modifications. It also reports that current findings show metformin can alter the gut microbiota by increasing short-chain fatty acid producing bacteria. The abstract links this to other systemic pathways that may aid in lowering inflammation, increasing metabolic fitness and keeping epigenetic stability. These are described as effects at the molecular level, not as proven human lifespan benefits.
Supporting source [1]
TAME trial aims to test age-associated diseases
The abstract presents the Targeting Ageing with Metformin (TAME) trial as a landmark trial that seeks to evaluate metformin's ability to slow down several age-associated diseases. It states that this trial could lead to a paradigm shift in the clinical approach to aging. The abstract does not report TAME results, participant numbers, follow-up or outcome measures; it describes the trial as planned or ongoing work. The article is said to consolidate findings from cellular, molecular and organismal levels and to call for more studies and trials on metformin and aging.
Supporting source [1]
Abstract-only scope of this metformin review
This record is an abstract of a review article; the full text was not reviewed. The abstract names no specific studies, sample sizes or human lifespan outcomes, and it does not establish that metformin slows aging or prevents disease in people. Statements about molecular pathways and gut microbiota are presented as findings from cellular, molecular and organismal research, and the abstract itself calls for more studies and trials. The TAME trial is described as seeking to evaluate effects, not as having shown them.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No specific studies, sample sizes, follow-up or human lifespan outcomes are reported, and the abstract calls for more studies and trials.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Manneh J, Alasmar M, Hajj NE. · europepmc.org · August 10, 2026